Zymeworks/$ZYME
About Zymeworks
Ticker
Industry
Employees
Zymeworks Metrics
$938M
-
-$1.52
1.10
-
Price and volume
Market cap
$938M
Beta
1.1
52-week high
$17.11
52-week low
$7.97
Average daily volume
525K
Financial strength
Current ratio
4.097
Quick ratio
3.824
Long term debt to equity
4.716
Total debt to equity
5.526
Management effectiveness
Return on assets (TTM)
-14.69%
Return on equity (TTM)
-28.73%
Valuation
Price to revenue (TTM)
16.398
Price to book
2.58
Price to tangible book (TTM)
2.72
Price to free cash flow (TTM)
-17.262
Growth
Revenue change (TTM)
-86.52%
Earnings per share change (TTM)
-150.18%
3-year revenue growth (CAGR)
40.37%
3-year earnings per share growth (CAGR)
-30.10%
What the Analysts think about Zymeworks
Analyst Ratings
Zymeworks Financial Performance
Income Statement
Q3 24
QoQ growth
$37B
-39.75%
$45B
107.52%
37.65%
6.78%
Zymeworks Earnings Performance
Earnings per share (EPS)
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
$3.69
$2.85
$2.45
$2.42
-
$3.55
$2.61
$2.05
$2.31
$3.94
3.94%
9.20%
19.51%
4.63%
-
Zymeworks News
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
FAQs
What’s the current market cap for Zymeworks stock?
What is the P/E ratio for Zymeworks stock?
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.